Kompakt und kompetent Startseite   Ärzte   Fachrichtungen   Studien   Terminvereinbarung   Vorlesungen   Presse   Links   Impressum



Adresse:
Schaubstraße 16
60596 Frankfurt/Main
Fon: 069 / 65 00 73 - 100
Fax: 069 / 65 00 73 - 150

Gynäkologische Abteilung:
Fon: 069 / 650073-117

Anfahrt mit der Straßenbahn:
Linien 12, 15, 16, 19 und 21
„Stresemannallee/Gartenstraße”

Anfahrt mit der S-Bahn:
Linien S3 und S4
„Stresemannallee”

info@krebszentrum-schaubstrasse.de


Kooperationen:

Stresemannallee 3
60596 Frankfurt/Main
Fon: 069 / 65 00 73 - 200
Fax: 069 / 65 00 73 - 250
www.ifs-frankfurt.de


www.infektiologikum.de


www.fbt-frankfurt.de



www.palliativteam-frankfurt.de

Prof. Dr. med. Kai Uwe Chow

Publikationsverzeichnis

Zurück | Presse

Publikationen (Originalarbeiten)

  1. Pelinkovic D, Lorcher U, Chow KU, Kronenberger H, Buhl R.
    Spirometric gated quantitative computed tomography of the lung in healthy smokers and non-smokers.
    Invest Radiol, 1997, 32: 335-43.

  2. Rummel MJ, Chow KU, Jager E, Hossfeld DK, Bergmann L, Peters HD, Hansmann ML, Meyer A, Hoelzer D, Mitrou PS.
    Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
    Ann Oncol, 1999, 10: 115-7.

  3. Weidmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, Adam S, Hor G, Hoelzer D, Mitrou PS.
    Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease.
    Leuk Lymphoma, 1999, 34: 545-51.

  4. Rummel MJ, Chow KU, Jager E, Leimer L, Hossfeld DK, Bergmann L, Peters HD, Hansmann ML, Meyer A, Hoelzer D, Mitrou PS.
    Intermittend 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle-cell lymphomas.
    Leuk Lymphoma, 1999, 35: 129-38.

  5. Chow KU, Rummel MJ, Weidmann E, Ries J, Jantschke P, Boehrer S, Pourebrahim F, Napieralski S, Stein J, Martin H, Hoelzer D, Mitrou PS.
    Induction of apoptosis by 2-chloro-2‘deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone.
    Leuk Lymphoma, 2000, 36: 559-67.

  6. Chow KU, Ries J, Weidmann E, Pourebrahim F, Napieralski S, Stieler M, Boehrer S, Rummel MJ, Stein J, Hoelzer D, Mitrou PS.
    Induction of apoptosis using 2‘,2‘difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic or myeloid cells. Antagonism or synergism depend on incubation schedule and origin of neoplastic cells.
    Ann Hematol, 2000, 79: 485-92.

  7. Boehrer S, Hinz T, Schui DK, Harder S, Chow KU, Schneider B, Hoelzer D, Mitrou PS, Weidmann E.
    T-large granular lymphocyte leukemia with natural killer cell-like cytotoxicity and expression of two different alpha- and beta-T-cell receptor chains.
    Br J Hematol, 2001, 112: 201-3.

  8. Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR.
    Changing incidence and survival in patients with aids-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy (HAART).
    Leuk Lymphoma, 2001, 41: 105-16.

  9. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E.
    In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lmyphoma using combinations of established cytotoxic drugs with bendamustine.
    Haematologica, 2001, 86: 485-93.

  10. Boehrer S, Chow KU, Pucetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E.
    Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia.
    Hematol J, 2001, 2: 103-7.

  11. Weidmann E, Boehrer S, Chow KU, Engels K, Harder L, Hinz T, Janssen O, Kriener S, Rummel MJ, Siebert R, Kabelitz D, Hansmann ML, Hoelzer D, Mitrou PS.
    Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide, and doxorubicine.
    Onkologie, 2001 24: 164-4.

  12. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases.
    Haematologica, 2002, 87: 33-43.

  13. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Pucetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E.
    In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation.
    Cancer Res, 2002, 62: 1768-75.

  14. Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D, Weidmann E, Mitrou PS.
    Induction of apoptosis by cladribine (2-CdA), gemcitabine and other cytotoxic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.
    Leuk Lymphoma, 2002, 43: 377-84.

  15. Rummel MJ, Chow KU, Karakas T, Jager E, Mezger J, von Grunhagen U, Schalk K, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS.
    Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin’s lymphoma.
    Eur J Cancer, 2002, 38: 1739-46.

  16. Boehrer S, Schui DK, Chow KU, Hoelzer D, Mitrou PS, Weidmann E.
    Cytotoxic activity of T- and NK-cell lymphoma cells is not dependent on a mature cytotoxic phenotype.
    Leuk Lymphoma, 2002, 43: 2363-68.

  17. Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, Mitrou PS, Weidmann E.
    In AML cell lines ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential.
    Leuk Lymphoma, 2003, 44: 165-73.

  18. Kim, SZ, Zollner TM, Schui DK, Chow KU, Sterry W, Kriener S, Hoelzer D, Mitrou PS, Weidmann E.
    CD4+/CD56+ neoplasia. Clinical features with emphasis on cytotoxic drug-induced apoptosis and expression of sialyl Lewis X, and a review of the 57 so far reported cases.
    Leuk Lymphoma, 2003, 44: 281-89.

  19. Chow KU, Nowak D, Boehrer S, Ruthardt M, Knau A, Hoelzer D, Mitrou PS, Weidmann E.
    Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of XIAP, cIAP1, par-4 and daxx and with enforced caspase activation.
    Biochem Pharmacol, 2003, 66 (5):711-24.

  20. Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus.
    Leuk Lymphoma 2004, 45 (7): 1429-1436.

  21. Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    In BCR-ABL-Positive Myeloid Cells Resistant to Conventional Chemotherapeutic Agents, Expression of Par-4 Increases Sensitivity to Imatinib (STI571) and Histone Deacetylase-Inhibitors.
    Biochemical Pharmacology 2004, 68 (1), 85-93.

  22. Boehrer S, Brieger A, Schaaf S, Kucoc-Zivojnov N, Nowak D, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    In the Erythroleukemic Cell Line HEL Prostate-Apoptosis-Response-Gene-4 (Par-4) Fails to Down-Regulate Bcl-2 and to Promote Apoptosis.
    Leuk Lymphoma 2004, 45 (7): 1445-1451.

  23. Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, Horst AH, Brodt HR.
    Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    British Journal of Haematology 2004, 125 (4): 455-462.

  24. Kukoc-Zivojnov N, Puccetti E, Chow KU, Bergmann M, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S.
    In Hematopoietic Cells Par-4 Abrogates the Survival Function of p185BCR-ABL .
    Experimental Hematology 2004, 32 (7): 649-56.

  25. Kim SZ, Chow KU, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer SA, Harder L, Hoelzer D, Mitrou PS, Weidmann E.
    Expression of ZAP-70 protein correlates with disease stage in chronic lymphatic leukemia and is associated with, but not generally restricted to non-mutated Ig VH status.
    Leuk Lymphoma 2004, 45 (10): 2037-45.

  26. Bergmann M, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S.
    Prostate-Apoptosis-Response-Gene-4 Sensitizes Neoplastic Lymphocytes to CD95-Induced Apoptosis.
    Ann Hematol 2004, 83 (10): 646-53.

  27. Boehrer S, Nowak D, Schaaf S, Bergmann M, Brieger A, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    In Malignant Myeloid Cells Expression of Daxx Down-Regulates Expression of p53 and of the Inhibitors of Apoptosis Proteins.
    Hematol J 2004, 5 (6): 513-518.

  28. Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Zeuzem S, Chow KU.
    Antioxidative treatment prevents activation of death receptor- and mitochondrion-dependent apoptosis in the heart of diabetic rats.
    Diabetologia 2004, 47 (12): 2072-2080.

  29. Boehrer S, Kukoc-Zivojnov N, Nowak D, Bergmann M, Baum C, Puccetti E, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Upon Drug-Induced Apoptosis Expression of Prostate-Apoptosis-Response-Gene-4 Promotes Cleavage of Caspase-8, Bid and Mitochondrial Release of Cytochrome C.
    Hematology 2004, 9 (5-6): 425-431.

  30. Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS, Chow KU.
    In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
    Anti-Cancer-Drugs 2005, 16 (1): 87-91.

  31. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU.
    Changing Incidence and Prognostic Factors of AIDS-related Non-Hodgkin's Lymphoma (ARL) in the Era of Highly Active Antiretroviral Therapy (HAART).
    Leuk Lymphoma 2005, 46 (2): 207-15.

  32. Boehrer S, Kukoc-Zivojnov N, Nowak D, Schaaf S, Kim SZ, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Expression of Daxx Sensitizes Jurkat T-Cells to the Apoptosis-Inducing Effect of Chemotherapeutic Agents.
    Pharmacol Res 2005, 51 (4): 367-374.

  33. Boehrer S, Nowak D, Hochmuth S, Kim SZ, Trepohl B, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Overexpression of Daxx in T-lymphoblastic Jurkat-cells enhances death receptor- and drug-induced apoptosis in distinct ways.
    Cell Signal 2005, 17 (5): 581-595.

  34. Rummel MJ, Al-Bartran S, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS.
    Bendamustine plus Rituximab (BR) is Effective and has a Favorable Toxicity Profile in the Treatment of Mantle-Cell and Low-Grade Non-Hodgkin's Lymphoma.
    J Clin Oncol 2005, 23 (15): 3383-3389.

  35. Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Mitrou PS, Hoelzer D, Weidmann E, Hofmann WK.
    In vivo drug-response in leukemic Non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression analysis.
    Pharmacol Res 2006, 53 (1): 49-61.

  36. Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, Trepohl B, Schneider B, Hoelzer D, Mitrou PS, Chow KU.
    Prostate-Apoptosis-Response-Gene-4 Increases Sensitivity to TRAIL-Induced Apoptosis.
    Leuk Res 2006, 30 (5): 597-605.

  37. Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, Jager H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou PS.
    Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
    Ann Oncol 2006, 17 (6): 914-919.

  38. Glienke W, Chow KU, Bauer N, Bergmann L.
    Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds.
    Leuk Lymphoma 2006, 47 (8): 1629-38.

  39. Friedmann I, Atmaca A, Chow KU, Jaeger E, Weidmann E.
    Additive Effects of Valproic Acid and Mitomycin C in Adenocarcinoma Cell Lines and Fresh Tumor Cells From Patients with Colon Cancer.
    J Chemotherapy 2006, 18 (4): 415-20.

  40. Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H.
    Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma.
    Leuk Lymphoma 2006, 48 (2): 349-56.

  41. Chow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D, Mitrou PS, Bergmann L, Ottmann OG, Boehrer S.
    The tyrosine kinase inhibitor AMN107 induces cell death in lymphoma cell lines by employing classical pathways of apoptosis.
    Leuk Lymphoma 2007, 48 (7): 1379-88.

  42. Nowak D, Boehrer S, Hochmuth S, Trepohl B, Hofmann W, Hoelzer D, Hofmann WK, Mitrou PS, Ruthardt M, Chow KU.
    Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs. 2007, 18(9):981-95.

  43. Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS.
    Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008, 57(3):411-23.

  44. Warzecha J, Göttig S, Chow KU, Brüning C, Percic D, Boehrer S, Brude E, Kurth A.
    Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother. 2007, 19(5):554-61

  45. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS.
    A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma. 2010, 51(3):447-55.

  46. Tsaur I, Probst M, Chow KU, Renne C, Cerovac I, Pelekanos C, Juengel E, Wedel SA, Bickeböller R, Karalis A.
    Gross haematuria as the primary symptom of extramedullary IgM plasmacytoma of the bladder. Urologe A. 2010, 47(7):850-4.

  47. Boehrer S, Schroeder P, Mueller T, Atz J, Chow KU.
    Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism. Anticancer Drugs. 2011, 22(6):519-30.

  48. Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L.
    Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol. 2011, 87(5):426-33.

  49. Chow KU.
    News on hypomethylating agents: Chasing the FOX. Cell Cycle. 2011, 10(18):3050.

Übersichtsartikel (Reviews) und Letter

  1. Chow KU, Schneider B, Mitrou PS, Weidmann E.
    Influence of various cytokines on the expression of CD20 on the surface of CLL-cells in vitro.
    Leuk Res, 2001, 25: 99-100.

  2. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E.
    In vitro studies with bendamustine: Enhanced activity in combination with rituximab.
    Semin Oncol, 2002, 29 (Suppl 13): 12-4.

  3. Boehrer S, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E.
    Expression and function of prostate-apoptosis-response-gene-4 in lymphatic cells.
    Leuk Lymphoma, 2002, 43: 1737-41.

  4. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU.
    Prostate-apoptosis-response-gene-4: biological properties and their potential therapeutic exploitation in hematological malignancies.
    Letters of Drug Design and Discovery 2005, 2 (4): 266-273.

  5. Otto B, Buchkremer M, Chow KU, Weidauer S, Neumann-Haefelin T.
    Differenzialdiagnostik einer thrombotisch thrombozytopenischen Purpura (TTP, Moschkowitz-Syndrom).
    Akt Neurol 2005, 32: 162-164.

  6. Chow KU, Nowak D, Hofmann W, Schneider B, Hofmann WK.
    Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4.
    Leukemia 2005, 19 (6): 1103-1105.

  7. Rickerts V, Brodt HR, Schneider B, Weidmann E, Chow KU.
    Host factors and disease severity in two patients with SARS.
    J Lab Med 2006, 30 (1): 18-22.

  8. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU.
    Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoetic Malignancies.
    Curr Pharm Des 2006, 12 (1): 111-20.

  9. Boehrer S, Nowak D, Hoelzer D, Chow KU.
    The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignancies.
    Curr Med Chem 2006, 13 (18): 2091-100.

Buchbeiträge

  1. Chow KU, Mitrou PS.
    Primäre ZNS-Lymphome (PCNSL). Mitrou PS (Hrsg.). Non-Hodgkin-Lymphome, Tumorzentrum Rhein/Main Selbstverlag, 1. Auflage 2001: 203-8.

  2. Chow KU, Mitrou PS.
    HIV-assoziierte Non-Hodgkin-Lymphome. Mitrou PS (Hrsg.). Non-Hodgin-Lymphome, Tumorzentrum Rhein/Main Selbstverlag, 1. Auflage 2001: 261-69.

  3. Mitrou PS, Chow KU.
    Kaposi-Sarkom. Schmoll HJ, Höffken K, Possinger G (Hrsg.). Kompendium der internistischen Onkologie, Springer-Verlag, 4. Auflage, 2006: 5251-5264, Band 2, 728-732, Band 3.

  4. Mitrou PS, Chow KU, Ruhnke M.
    HIV-assoziierte Tumoren. Schmoll HJ, Höffken K, Possinger G (Hrsg.). Kompendium der internistischen Onkologie, Springer-Verlag, 4. Auflage, 2006: 3146-3164, Band 2, 169-172, Band 3.

  5. Hoffmann C, Chow KU.
    HIV-assoziierte Lymphome. Rummel MJ (Hrsg.). NHL- Diagnostik und Therapie, State of the Art 2007. Agileum Verlag GmbH, München, 2007: 276-85.

Kurzpublikationen (Abstracts) und Vorträge

  1. Möller B, Chow KU, Kaltwasser JP. Psychogene Armparese und Schulter-Arm-Syndrom: Fehldiagnosen einer in Deutschland selteneren Ursache für rheumatische Beschwerden mit spezifischem Therapieansatz. Z Rheumatol 1997 (Suppl 1):51 (P102)

  2. Chow KU, Rummel M, Weidmann E, Klein S, Hoelzer D, Bergmann L, Mitrou PS. In vitro induced apoptosis by 2-chlorodeoxyadenosine (2-CdA) in lymphocytes shows potential synergism in different cytostatic combinations. Onkologie 1997, 20 (Suppl 1): page44 (154)

  3. Mitrou PS, Chow KU, Rummel M, Jantschke P, Weidmann E, Hoelzer D, Bergmann L. Synergistic effects of 2-CdA and other cytotoxic drugs on apoptosis of normal and neoplastic lymphocytes. J Cancer Res Clin Oncol 1998, 124 (Suppl 1): R59 (14.28.02)

  4. Chow KU, Rummel MJ, Weidmann E, Jantschke P, Pourebrahim F, Boehrer S, Hoelzer D, Mitrou PS. Induction of apoptosis in vitro by 2-CdA in combination with other cytotoxic drugs on normal and neoplastic lymphocytes. Ann Hematol 1998, 77 (Suppl 2): S37 (146)

  5. Pourebrahim F, Chow KU, Rummel MJ, Jantschke P, Stieler M, Hoelzer D, Mitrou PS, Weidmann E. Apoptotic effects by combinations of gemcitabine with 2-CdA on lymphatic and myeloid cell lines depend on incubation periods. Ann Hematol 1998, 77 (Suppl 2): S38 (147)

  6. Boehrer S, Rummel MJ, Martin H, Chow KU, Hoelzer D, Mitrou PS. Mobilization of CD34+ cells in patients with low-grade non-Hodgkin's lymphomas before and after treatment with 2-chlorodeoxyadenosine (2-CdA). Ann Hematol 1998, 77 (Suppl 2): S150 (596)

  7. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS. 2-CdA (2-chlorodeoxyadenosine) plus mitoxantrone in the treatment of low-grade non-Hodgkin's lymphomas - preliminary results of a phase-II study. Ann Hematol 1998, 77 (Suppl 2): S150 (597)

  8. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS. 2-CdA (2-chlorodeoxyadenosine) plus mitoxantrone in the treatment of low-grade non-Hodgkin's lymphomas - preliminary results of a phase-II study. Proceedings of the American Society of Clinical Oncology 1999, 18: 35a (130)

  9. Chow KU, Rummel MJ, Weidmann E, Ries J, Jantschke P, Boehrer S, Pourebrahim F, Martin H, Stein J, Hoelzer D, Mitrou PS. Induction of apoptosis by 2-CdA alone and in combination with other cytotoxic drugs on normal and neoplastic lymphocytes. Proceedings of the American Society of Clinical Oncology 1999, 18: 182a (698)

  10. Chow KU, Geduldig K, Mitrou PS, Brodt HR. Prevalence and outcome of non-Hodgkin's lymphomas in 258 patients of the Frankfurt AIDS cohort study (FACS). European Journal of Medical Research 1999, 4 (Suppl 1): p42 (F1264)

  11. Boehrer S, Godzisard S, Karakas T, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. Expression of Par-4 (prostate apoptosis response gene-4) in normal and neoplastic lymphocytes. Onkologie 1999, 22 (Suppl 1): p54 (183)

  12. Chow KU, Geduldig K, Helm EB, Hoelzer D, Mitrou PS, Brodt HR. Prevalence and outcome of non-Hodgin's lymphomas in 258 patients of the Frankfurt AIDS cohort study (FACS) in the years of 1983-1999. Onkologie 1999, 22 (Suppl 1): p149 (562)

  13. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS. Cladribine (2-CdA) plus mitoxantrone in the treatment of low-grade non-Hodgkin's lymphomas - preliminary results of a phase-II study. Onkologie 1999, 22 (Suppl 1): p155 (587)

  14. Boehrer S, Chow KU, Ries J, Weidmann E, Pourebrahim F, Napieralski S, Stieler M, Rummel MJ, Hoelzer D, Mitrou PS. Induction of apoptosis by gemcitabine in combination with other cytotoxic drugs on malignant lymphatic and myeloid cells: Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Blood 1999, 94 (10) (Suppl 1): p191b (4040)

  15. Chow KU, Stieler M, Martin H, Rummel MJ, Weidmann E, Hoelzer D, Mitrou PS. Induction of apoptosis by chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells. Blood 1999, 94 (10) (Suppl 1): p154b (3861)

  16. Rummel MJ, Chow KU, Karakas T, Jaeger E, Mezger J, Kaefer G, Boehrer S, Bergmann L, Martin H, Hoelzer D, Mitrou PS. Cladribine (2-Chlorodeoxyadenosine, 2-CdA) plus mitoxantrone in the treatment of progressive advanced low-grade non-Hodgkin's and mantle cell lymphomas- Preliminary results of a phase-II study. Blood 1999, 94 (10) (Suppl 1): p660a (2931)

  17. Boehrer S, Chow KU, Pucetti E, Ruthardt M, Godzisard S, Hoelzer D, Mitrou PS, Weidmann E. The expression of prostate apoptosis response gene-4 (Par-4) and Bcl-2 in normal and neoplastic lymphocytes. Proceedings of the American Association for Cancer Research 2000, 41: p407 (2587)

  18. Chow KU, Weidmann E, Rummel MJ, Martin H, Stieler M, Hoelzer D, Mitrou PS. Comparison of induction of apoptosis by cytotoxic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells. Proceedings of the American Society of Clinical Oncology 2000, 19: p64a (248)

  19. Boehrer S, Hinz T, Schui D, Harder S, Schneider B, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. T-large granular lymphocyte leukemia with natural killer-cell like cytotoxicity and expression of two different a- and ß-TCR chains. Onkologie 2000, 23 (Suppl 7): p117 (0437)

  20. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS. for the 2-CdA study group: Jaeger E, Kaefer E, Mezger J, Westerhausen M, Schalk K, Hecker R, Karakas T, Fischer M, Bergmann L. Cladribine (2-CdA) plus mitoxantrone in the treatment of mantle-cell and low-grade lymphomas. Onkologie 2000, 23 (Suppl 7): p151 (0572)

  21. Boehrer S, Chow KU, Beske F, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. Prostate-apoptosis-response-gene-4 is widly expressed in lymphatic cells and promotes apoptosis by down-regulating Bcl-xL and by inducing premature and enhanced activation of caspase-3. Blood 2000, 96 (11): p80a (342)

  22. Boehrer S, Chow KU, Pucetti E, Ruthardt M, Beske F, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. In lymphatic cells prostate apoptosis response gene-4 facilitates apoptosis by down-regulation of Bcl-2 as well as enforcing disruption of mitochondrial membrane potential and increasing caspase-3-like activity. Proceedings of the American Association for Cancer Research 2001, 42: p592 (3183)

  23. Chow KU, Nowak D, Boehrer S, Knau A, Napieralski S, Hoelzer D, Mitrou PS, Weidmann E. Antagonistic and synergistic effects on drug-induced apoptosis show specific expression patterns of regulator proteins. Hematol J 2001, 1 (Suppl 1): p70 (241)

  24. Chow KU, Dommerlad D, Boehrer S, Schneider B, Hoelzer D, Mitrou PS, Weidmann E. Anti-CD20 antibody (IDEC-C2B8, Rituximab) sensitizes drug-induced apoptosis in vitro. Effects of complement, cytokines and caspase-3. Hematol J 2001, 1 (Suppl 1): p160 (581)

  25. Boehrer S, Chow KU, Beske F, Puccetti E, Ruthardt M, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. Functional role of prostate-apoptosis-response-gene-4 in apoptosis of neoplastic lymphocytes. Hematol J 2001, 1 (Suppl 1): p71 (244)

  26. Chow KU, Dommerlad D, Boehrer S, Schneider B, Hoelzer D, Mitrou PS, Weidmann E. Anti-CD20 antibody (IDEC-C2B8, Rituximab) enhances drug-induced apoptosis in vitro. Effects of complement, cytokines and caspases. Onkologie 2001, 24 (Suppl 6): p129 (490)

  27. Boehrer S, Chow KU, Beske F, Pucetti E, Ruthardt M, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. Functional role of prostate-apoptosis-response-gene 4 in apoptosis of neoplastic lymphocytes. Onkologie 2001, 24 (Suppl 6): p55 (200)

  28. Chow KU, Nowak D, Boehrer S, Schneider B, Hoelzer D, Mitrou PS, Weidmann E. Activation of caspase-3, -6, -7, -8 and -9 as well as downregulation of XIAP and c-IAP1 in a lymphoma cell line model of synergistic and antagonistic cytotoxic drug-induced apoptosis. Blood 2001, 98 (11): p136b (4212)

  29. Rummel MJ, Kim SZ, Chow KU, Weidmann E, Bergmann L, Hoelzer D, Mitrou PS. Bendamustine and Rituximab act synergistically in vitro and are effective in the treatment of indolent and mantle-cell lymphomas preatreted with purine analogs. Blood 2001, 98 (11): p248b (4721)

  30. Boehrer S, Chow KU, Kukoc-Zivojnov N, Pucetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. Overexpression of Prostate-Apoptosis-Response-Gene-4 enables lymphatic cells to circumvent abrogation of caspase-3-activity by inducing activation of caspase-9 and -7. Blood 2001, 98 (11): p556a (2327)

  31. Boehrer S, Chow KU, Kukoc-Zivojnov N, Pucetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. Prostate-Apoptosis-Response-Gene-4 enables neoplastic lymphocytes to circumvent abrogation of caspase-3 by inducing activation of caspase-6, -7 and –9 and down-regulation of cIAP1 and XIAP. Hematol J 2002, 3 (Suppl 1): p149 (495)

  32. Rummel MJ, Kim SZ, Chow KU, Weidmann E, Hoelzer D, Mitrou PS. Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of indolent and mantle-cell lymphomas pretreated with purine analoges. Onkologie 2002, 25 (Suppl 4): p62 (214)

  33. Hoffmann C, Chow KU, Wolf E, Fätkenheuer G, Stoehr A, Plettenberg A, Stellbrink HJ, Buhk T, van Lunzen J, Wasmuth JC, Rockstroh HJ, Jäger H, Horst HA, Brodt HR. HIV-associated Hodgkin's disease in the era of highly active antiretroviral therapy (HAART) - is there an improvement in survival. Onkologie 2002, 25 (Suppl 4): p144 (504).

  34. Boehrer S, Chow KU, Kukoc-Zivojnov N, Pucetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS, Weidmann E. Expression of prostate-apoptosis-response-gene 4 enhances activation of caspase-8 and enables neoplastic lymphocytes to circumvent inhibition of caspase-3 by down-regulating inhibitors of apoptosis proteins. Onkologie 2002, 25 (Suppl 4): p249 (879)

  35. Chow KU, Nowak D, Boeher S, Ruthardt M, Knau A, Hoelzer D, Mitrou PS, Weidmann E. In lymphatic cells synergistic effects of apoptosis induced by chemotherapeutic drug combinations are dependent on enforced caspase activation and concomitant down-regulation of XIAP and cIAP1. Onkologie 2002, 25 (Suppl 4): p249 (880)

  36. Kukoc-Zivojnov N, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S. Overexpression of prostate-apoptosis-response-gene-4 antagonizes factor-dependency induced by ras and bcr-abl. Blood 2002, 100 (11): p741a (2928)

  37. Chow KU, Nowak D, Boehrer S, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E. Synergistic effects of chemotherapeutic drugs are dependend on enforced caspase activation an down-regulation of XIAP, cIAP1, Par-4 and Daxx. Blood 2002, 100 (11): p323a (2152)

  38. Hoffmann C, Chow KU, Wolf E, Fäktenheuer G, Wöhrmann A, Stoehr A, Plettenberg A, Lorenzen T, Stellbrink HJ, Wasmuth JC, Rockstroh HJ, Mostaf F, Jäger H, Horst HA, Brodt HR. HIV-associated Hodgkin's disease (HD) in the era of highly active antiretroviral therapy (HAART). CROI 2003.

  39. Kukoc-Zivojnov N, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S. Overexpression of prostate-apoptosis-response-gene-4 antagonizes factor-dependency induced by ras and bcr-abl. Apoptosis 2003.

  40. Kukoc-Zivojnov N, Chow KU, Valles Uriarte L, Hoelzer D, Mitrou PS, Ruthardt M, Weidmann E, Boehrer S. In Lymphatic and Myeloid Cell Lines Prostate-Apoptosis-Reponse-Gene-4 Antagonizes Factor-Independent Growth Caused by p185bcr-abl by Hindering Activation of Ras. Proceedings of the American Association of Cancer Research 2003, Volume 44, (abstract 320).

  41. Kim SZ, Rummel MJ, Chow KU, Duerk HA, Ganser A, Mitrou PS. Bendamustine plus rituximab is highly effective in the treatment of advanced low-grade and mantle cell lymphomas with unfavorable prognosis. Proceedings of the American Society of Clinical Oncology 2003, 22: 592 (abstract 2380).

  42. Wolf T, Chow KU, Brodt HR. Evolving Characteristics of HIV-related Hodgkin's Lymphoma in the HAART-Era in the Frankfurt Cohort and Elsewhere. European Journal of Medical Research 2003, 8 (Suppl 1): 58 (abstract 132).

  43. Kukoc-Zivojnov N, Chow KU, Bergmann M, Baum C, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S. In Neoplastic Lymphocytes Par-4 Promotes Signaling of the Extrinsic Pathway without the Requirement of Death Receptor Stimulation. Onkologie 2003, Suppl 5, 26: p165 (P837).

  44. Kim SZ, Chow KU, Kukoc-Zivojnov N, Steimle-Grauer S, Harder L, Hoelzer D, Mitrou PS, Weidmann, E. Zap-70 Protein assoziert mit dem Mutationsstatus und dem Stadium bei der chronischer lymphatischen Leukämie. Onkologie 2003, Suppl 5, 26: p167 (P845).

  45. Rummel MJ, Kim SZ, Chow KU, Welslau M, Al-Batran S, Kofahl-Krause D, Rost A, Josten KM, Hecker R, von Gruenhagen U, Neise M, Hoelzer D, Mitrou PS. Bendamustine and Rituximab Act Synergistically in vitro and are Effective in the Treatment of Relapsed or Refractory Indolent and Mantle-Cell Lymphomas. Blood 2003, 102, 11: 104a (abstract 353).

  46. Bergmann M, Kukoc-Zivojnov N, Chow KU, Pucetti E, Ruthardt M, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S. Prostate-Apoptosis-Response-Gene-4 Sensitizes Neoplastic Lymphocytes to CD95-induced Apoptosis. Blood 2003, 102, 11: 855a (abstract 3179).

  47. Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Chow KU, Zeuzem S. Langzeit-Hyperglykämie aktiviert Rezeptor- als auch Mitochondrion-vermittelte Apoptose im Herzmuskel diabetischer Ratten. Medizinische Klinik 2004, 99, 4: 104 (P187).

  48. Trojan J, Kim SZ, Engels K, Hoelzer D, Mitrou PS, Caspary WF, Chow KU. Optimierung der palliativen Chemotherapie bei Patienten mit metastasiertem Magenkarzinom durch in vitro Chemosensitivitätstestung. 2004

  49. Boehrer S, Schaaf S, Bergmann M, Brieger A, Nowak D, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. In Malignant Lymphocytes Expression of DAXX Increases Apoptosis by Promoting Extrinsic Siganling. Hematol J 2004, 5, (Suppl. 2): S64 (abstract 190).

  50. Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Chow KU, Zeuzem S. Antioxidative Behandlung verhindert die Aktivierung der Todesrezeptor- und der Mitochondrion-abhängigen Apoptose im Herzmuskel diabetischer Ratten. Diabetes und Stoffwechsel 2004, 14: 137 (abstract).

  51. Atta J, Holzmann I, Weber C, Chow KU, Mitrou PS, Hoelzer D, Martin H. Dexa-BEAM in relapsed/refractory Hodgkin’s and Non-Hodgkin-Lymphoma: a retrospective analysis of 215 patients. Onkologie 2004, 27, (Suppl. 3): S18 (abstract O113).

  52. Weidmann E, Krause S, Hess G, Dreyling M, Hebart H, Subklewe M, Falge C, Chow KU, Banat A, Filipp C, Al-Batran SE, Gramatzki M, Hansmann ML, Jäger E, Mitrou PS, on behalf of the „Study group peripheral T- and NK-cell neoplasias”. Treatment of peripheral (mature) T-cell lymphomas with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD). Preliminary results of a phase II study. Onkologie 2004, 27, (Suppl. 3): S19 (abstract O116).

  53. Boehrer S, Bergmann M, Kukoc-Zivojnov N, Sattler N, Hoelzer D, Mitrou PS, Chow KU. Par-4 Promotes TRAIL-Induced Apoptosis by Down-Regulating the Inhibitors of Apoptosis Proteins cIAP-1 and XIAP and by Increasing Activation of the Caspases-8, -9, -6 and -7. Onkologie 2004, 27, (Suppl. 3): S58 (abstract O429).

  54. Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, Mitrou PS, Hoelzer D, Weidmann E, Hofmann WK. In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin's Lymphomas is Predicted by in Vitro Chemosensitivity Testing and Gene Expression Profiling. Blood 2004, 104 (11): 2273.

  55. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Overexpression of Par-4 Increases TRAIL-Induced Apoptosis in Neoplastic Lymphocytes by Diminishing Expression of Inhibitors-of-Apoptosis-Proteins and by Enforcing Activation of Initiator- and Executionercaspases. Blood 2004, 104 (11): 4329.

  56. Weidmann E, Krause S, Hess G, Dreyling M, Hebart H, Subklewe M, Falge C, Chow KU, Banat A, Filipp C, Al-Batran SE, Gramatzki M, Hansmann ML, Jäger E, Mitrou PS, on behalf of the „Study group peripheral T- and NK-cell neoplasias”. Treatment of peripheral (mature) T-cell lymphomas with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD). Preliminary results of a phase II study. Blood 2004, 104 (11): 2640.

  57. Boehrer S, Puccetti E, Nowak D, Ruthardt M, Bergmann M, Sattler N, Hoelzer D, Mitrou PS, Chow KU. Prostate-Apoptosis-Response-Gene-4 Sensitizes Neoplastic Lymphocytes to TRAIL-Induced Apoptosis. Haematologica/Hematol J 2005, 90 (Suppl. 2): 194 (abstract 481).

  58. Nowak D, Boehrer S, Hochmuth S, Trepohl B, Hofmann W, Hoelzer D, Hofmann WK, Mitrou PS, Ruthardt M, Chow KU. New Src Kinase Inhibitors Induce Apoptosis and Mediate Cell Cycle Arrest in Lymphoma Cells Implicating a New Treatment Option. Onkologie 2005, 28 (Supplement 3): 195 (abstract 600).

  59. Chow KU, Kim SZ, Hipfel A, Hoelzer D, Rummel MJ, Bergmann L. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Epirubicin, and Rituximab (FER) as First- or Secondline Therapy for Chronic Lymphocytic Leukemia (CLL) and Prolymphocytic Leukemia (PLL). Onkologie 2005, 28 (Supplement 3): 264 (abstract 820).

  60. Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, Trepohl B, Schneider B, Hoelzer D, Mitrou PS, Chow KU. Prostate-Apoptosis-Response-Gene-4 Increases Sensitivity to TRAIL-Induced Apoptosis. Blood 2005, 106 (11): 2485.

  61. Kriener S, Engels K, Chow KU, Hansmann HL. A rare case of Hyperhaemoglobulinemia. DGP 2006. Kriener S, Engels K, Chow KU, Hansmann ML. Pathology, Research and Practice 2006, 202: 417.

  62. Chow KU, Kim SZ, Hermann S, Hoelzer D, Bergmann L. Fludarabine, Epirubicin, and Rituximab (FER) as First- or Secondline Therapy for Chronic Lymphocytic Leukemia (CLL) and Prolymphocytic Leukemia (PLL). Onkologie 2006, 29 (Supplement 3): 194 (abstract 808).

  63. Chow KU, Kim SZ, Hermann, S, Cordes HJ, Hipfel A, Bergmann L. Rituximab in combination with Fludarabine and Epirubicine is highly effective in the first-line treatment of chronic lymphocytic leukaemia. Onkologie 2007, 30 (Supplement 3): 88 (abstract p383).

  64. Chow KU, Kim-Wanner SZ, Hermann, S, Wunderle L, Cordes HJ, Bergmann L. Immunochemotherapy with rituximab in combination with fludarabine and epirubicine as first-line treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2010, 28: 7s (suppl; abstr 8075).

  65. Kunzmann V, Laurent G, Sicard H, Casasnovas O, Thieblemont C, Lafaye de Micheaux S, Derigs HG, Chow KU, Goebeler M, Einsele H, Rossi JF. Phase II study of treatment with IPH1101 and low dose of IL-2 in combination with rituximab re-treatment in patients with follicular lymphoma. Onkologie 2010, 33 (suppl 6): 158 (P539).

  66. Nebe CT, Atta J, Hensel M, Baldus M, Chow KU. Is persitent polyclonal B cell lymphocytosis a premalignant state for a clonal B cell lymphoma? Onkologie 2010, 33 (suppl 6): 254 (P843).